Primary outcomes were apnea-hypopnea index (AHI) and oxygen saturation nadir
The drug may be of clinical benefitin
Acetazolamide reduced the overall apnea-hypopnea index (mean difference
This study aimed to assess the
Results: Fifteen trials with a total of 256 patients were pooled in our systematic review
All controlled studies of acetazolamide in obstructive sleep apnea and/or central sleep apnea (CSA) were evaluated
The existence of high heterogeneity is an important limitation in applicability of our analysis
J Clin Sleep Med 2021;17: Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence
1–3 Positive airway pressure (PAP), whose main effect is keeping the upper airway open, is regarded as the
06
Sleep apnea is a disease with intermittent cessation and/or decrease of airflow during sleep
Acetazolamide reduced the apnea-hypopnea index (AHI) by a mean difference of 16 events/h for the 14 studies overall
Aim: To investigate the treatment effect of acetazolamide in patients with moderate OSA and obesity
Schmickl CN, Landry SA, Orr JE, et al
High-altitude periodic breathing in healthy mountain travelers and in patients with preexisting obstructive sleep apnea can be prevented or treated with acetazolamide, a drug that is also used for acute mountain sickness
It also can help rule out other sleep disorders, such as obstructive sleep apnea, repetitive movements during sleep or narcolepsy
To aid with patient selection for long-term trials and clinical care, our goal was to understand better the factors that determine the change in loop gain following acetazolamide in human subjects with sleep apnea
It is used to treat periodic breathing at high altitude
2) To examine alterations in the sleep EEG after short-term discontinuation of continuous positive airway pressure (CPAP) therapy
In the RePOSA study the low dose is 2